Has Gene Germano, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,272 in general payments to Gene Germano, MD across 104 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gene Germano, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gene Germano, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gene Germano, MD

Addiction Medicine · Norfolk, VANPI 1881870442

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.5% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 36.9% of the total. 2025 is the largest year on record at $1,567, 6.4 times the $244 reported in 2019. Among addiction medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,272in general payments, 2019–2025

Across 104 payments — averaging $31.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1K
Johnson & Johnson$528
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$278
Alkermes, Inc.$201
Janssen Scientific Affairs, LLC$200
Braeburn Inc.$179
plus $677 from 11 others

What the payments were for

Consulting fees$2006%
Food & beverage$3,05993%
Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	50	$1,208
Johnson & Johnson	9	$528
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	9	$278
Alkermes, Inc.	5	$201
Janssen Scientific Affairs, LLC	1	$200
Braeburn Inc.	8	$179
Indivior Inc.	8	$166
Sunovion Pharmaceuticals Inc.	1	$116
Vertex	1	$90
E.r. Squibb & Sons, L.L.C.	3	$81
Gilead	3	$74
USWM, LLC	1	$44
Axsome Therapeutics, Inc.	1	$26
TMS Neurohealth Centers Inc.	1	$23
Teva Pharmaceuticals USA, Inc.	1	$21
Neurocrine Biosciences, Inc.	1	$20
Otsuka America Pharmaceutical, Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,272 in reported general payments places this provider in the 95th percentile of 44 addiction medicine providers in Virginia.

See all addiction medicine providers in Virginia →

Medicare billing

Part B allowed, 2024

$50,451

Medicare patients

Services billed

579

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl	30	$2,455
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	14	$333
Clonidine Hcl	14	$295
Hydralazine Hcl	12	$183
Simvastatin	14	$108

Paid to pharmacies, not to this prescriber.

Other addiction medicine in Norfolk

Joshua MoranNorfolk$1K
Ivor PurchasNorfolk$18
Jeffrey KatraCharlottesville$59K
Masaru NishiaokiVirginia Beach$6K
Mitchell BurkenFredericksburg$3K
Nancye SadlerManassas$3K
Gilbert SchmidtVirginia Beach$3K
James GardnerRichmond$1K
Reymond Damasco PascualHampton$958
Ronald MejzakVirginia Beach$618

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →